Brief: Tiziana Announces Positive Clinical Data From A Secondary Progressive Multiple Sclerosis Patient Treated For Six Months With Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

Tiziana Life Sciences

10/03/2022 12:38

March 10 (Reuters) - Tiziana Life Sciences Ltd  TLSA.O :
    * TIZIANA ANNOUNCES POSITIVE CLINICAL DATA FROM A SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS PATIENT TREATED FOR SIX MONTHS
WITH INTRANASALLY ADMINISTERED FORALUMAB, A FULLY HUMAN ANTI-CD3
MONOCLONAL ANTIBODY
    * TIZIANA LIFE SCIENCES LTD - INTRANASAL FORALUMAB WAS
WELL-TOLERATED WITH NO ADVERSE REACTIONS OR LABORATORY
ABNORMALITIES
    * TIZIANA LIFE SCIENCES LTD - DATA SHOW SUSTAINED INHIBITION
OF
MICROGLIAL ACTIVATION AS ASSESSED BY POSITRON EMISSION
TOMOGRAPHY
    * TIZIANA LIFE SCIENCES LTD - FDA HAS ALLOWED A SECOND
PATIENT TO
RECEIVE INTRANASAL FORALUMAB THERAPY UNDER A SEPARATE
SINGLE-PATIENT EXPANDED ACCESS IND

Source text for Eikon:  ID:nGNX45fNZs 
Further company coverage:  TLSA.O